Skip to main content
SpringerLink
Log in

Prognostisch relevant

Genexpressionsanalysen bei Patientinnen mit frühem Brustkrebs

  • Zertifizierte Fortbildung
  • Published:
gynäkologie + geburtshilfe Aims and scope

Zusammenfassung

Bei manchen Patientinnen mit frühem, Hormonrezeptor-positivem, HER2-negativem Mammakarzinom ist die Indikation für eine zusätzliche Chemotherapie (adjuvant/neoadjuvant) auf Basis klinisch-pathologischer Faktoren nicht eindeutig zu stellen. Genexpressionsanalysen können die Entscheidungsfindung für oder gegen eine Chemotherapie unterstützen. In Deutschland sind mehrere Tests kommerziell erhältlich, die über eine breite Evidenzbasis verfügen. Sie sollten nicht als Ersatz etablierter diagnostischer Schritte gesehen werden, aber sie können in einem definierten Einsatzbereich hilfreiche Zusatzinformationen liefern.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Coates AS et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. AGO Kommission Mamma. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Guidelines of the AGO Breast Committee. Letzte Aktualisierung: 02.03.2017; http://www.ago-online.de/fileadmin/downloads/leitlinien/mamma/2017-03/AGO_deutsch/PDF_Gesamtdatei_deutsch/Alle aktuellen Empfehlungen_2017.pdf

  3. Harbeck N, Gnant M. Breast cancer. Lancet 2017 Mar 18;38910074)):1134–50

    Article  PubMed  Google Scholar 

  4. Dubsky P et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013;243)):640–7.

    Article  CAS  PubMed  Google Scholar 

  5. Filipits M et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;1718)):6012–20.

    Article  CAS  PubMed  Google Scholar 

  6. Martin M et al. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Res. 2014;162)):R38.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Dubsky P et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer. 2013;10912)):2959–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Müller BM et al. Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections. J Clin Pathol. 2012;657)):660–2.

    Article  PubMed  PubMed Central  Google Scholar 

  9. van’t Veer LJ Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;4156871)):530–6.

    Article  Google Scholar 

  10. van de Vijver MJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;34725)):1999–2009.

    Article  CAS  PubMed  Google Scholar 

  11. Sapino A et al. MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue. J Mol Diagn. 2014;162)):190–7.

    Article  CAS  PubMed  Google Scholar 

  12. Krijgsman O et al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat. 2012;1331)):37–47.

    Article  CAS  PubMed  Google Scholar 

  13. Cardoso F et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 2008;265)):729–35.

    Article  PubMed  Google Scholar 

  14. Wuerstlein R et al. Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study. SABCS. 2016: P6-09-10.

    Google Scholar 

  15. Nielsen T et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 2014;14:177.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Gnant M et al. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Ann Oncol. 2015;268)):1685–91.

    Article  CAS  PubMed  Google Scholar 

  17. Sestak I et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol. 2015;338)):916–22.

    Article  CAS  PubMed  Google Scholar 

  18. Wuerstlein R et al. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer. Curr Med Res Opin. 2016;327)):1217–24.

    Article  CAS  PubMed  Google Scholar 

  19. Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;35127)):2817–26.

    Article  CAS  PubMed  Google Scholar 

  20. Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;2423)):3726–34.

    Article  CAS  PubMed  Google Scholar 

  21. Dowsett M et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;2811)):1829–34.

    Article  PubMed  Google Scholar 

  22. Gluz O et al. Prospective WSG Phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score® result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2- high risk node-negative and positive breast cancer patients. EBCC. 2016;Abstr 8LBA.

    Google Scholar 

  23. Gluz O et al. West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. J Clin Oncol. 2016;3420)):2341–9.

    Article  PubMed  Google Scholar 

  24. Sparano JA et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015;37321)):2005–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Hofmann D et al. WSG ADAPT — adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials. 2013;14:261.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Bartlett JM et al. Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. J Natl Cancer Inst. 2016;108(9).

    Article  Google Scholar 

  27. Sestak I et al. Comprehensive comparison of prognostic signatures for breast cancer in TransATAC. SABCS. 2016:Abstr S6–05.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brustzentrum der Universität München, Frauenklinik Campus Innenstadt und Großhadern, Marchioninistraße 15, 81377, München, Deutschland

    Nadia Harbeck

Authors
  1. Nadia Harbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nadia Harbeck.

Additional information

Interessenkonflikt

Frau Prof. Nadia Harbeck gibt folgende potenzielle Interessenkonflikte an: Honorare für Beratung oder Vorträge von den Firmen Agendia, Genomic Health und Nanostring.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harbeck, N. Genexpressionsanalysen bei Patientinnen mit frühem Brustkrebs. gynäkologie + geburtshilfe 22 (Suppl 1), 32–38 (2017). https://doi.org/10.1007/s15013-017-1053-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15013-017-1053-y

Search

Navigation